Original
Estudio aleatorizado con abciximab o eptifibatide en angioplastia coronaria compleja. Resultados intrahospitalarios y a 30 días
A comparative study between abciximab and eptifibatide as an adjuvant treatment in patients undergoing high risk percutaneous coronary angioplasty. In-hospital and 30 days follow-up outcomes
Leído
4725
Vecesse ha leído el artículo
1074
Total PDF
3651
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 21 | 4 | 25 |
| 2025 11 | 23 | 21 | 44 |
| 2025 10 | 27 | 15 | 42 |
| 2025 9 | 22 | 21 | 43 |
| 2025 8 | 16 | 18 | 34 |
| 2025 7 | 25 | 11 | 36 |
| 2025 6 | 14 | 8 | 22 |
| 2025 5 | 16 | 12 | 28 |
| 2025 4 | 17 | 9 | 26 |
| 2025 3 | 24 | 7 | 31 |
| 2025 2 | 32 | 10 | 42 |
| 2025 1 | 48 | 13 | 61 |
| 2024 12 | 43 | 4 | 47 |
| 2024 11 | 23 | 4 | 27 |
| 2024 10 | 19 | 5 | 24 |
| 2024 9 | 29 | 8 | 37 |
| 2024 8 | 26 | 8 | 34 |
| 2024 7 | 16 | 11 | 27 |
| 2024 6 | 14 | 9 | 23 |
| 2024 5 | 12 | 6 | 18 |
| 2024 4 | 12 | 6 | 18 |
| 2024 3 | 12 | 13 | 25 |
| 2024 2 | 15 | 18 | 33 |
| 2024 1 | 9 | 6 | 15 |
| 2023 12 | 26 | 7 | 33 |
| 2023 11 | 33 | 8 | 41 |
| 2023 10 | 19 | 6 | 25 |
| 2023 9 | 20 | 8 | 28 |
| 2023 8 | 21 | 7 | 28 |
| 2023 7 | 42 | 6 | 48 |
| 2023 6 | 55 | 5 | 60 |
| 2023 5 | 84 | 10 | 94 |
| 2023 4 | 42 | 3 | 45 |
| 2023 3 | 26 | 9 | 35 |
| 2023 2 | 23 | 12 | 35 |
| 2022 1 | 15 | 0 | 15 |
| 2022 12 | 31 | 6 | 37 |
| 2022 11 | 30 | 11 | 41 |
| 2022 10 | 22 | 16 | 38 |
| 2022 9 | 14 | 9 | 23 |
| 2022 8 | 17 | 9 | 26 |
| 2022 7 | 15 | 11 | 26 |
| 2022 6 | 20 | 10 | 30 |
| 2022 5 | 27 | 11 | 38 |
| 2022 4 | 19 | 14 | 33 |
| 2022 3 | 20 | 12 | 32 |
| 2022 2 | 41 | 11 | 52 |
| 2021 1 | 18 | 9 | 27 |
| 2021 12 | 49 | 11 | 60 |
| 2021 11 | 27 | 17 | 44 |
| 2021 10 | 13 | 15 | 28 |
| 2021 9 | 13 | 11 | 24 |
| 2021 8 | 6 | 15 | 21 |
| 2021 7 | 11 | 10 | 21 |
| 2021 6 | 9 | 12 | 21 |
| 2021 5 | 12 | 6 | 18 |
| 2021 4 | 36 | 21 | 57 |
| 2021 3 | 17 | 20 | 37 |
| 2021 2 | 6 | 14 | 20 |
| 2020 1 | 12 | 17 | 29 |
| 2020 12 | 12 | 6 | 18 |
| 2020 11 | 16 | 1 | 17 |
| 2020 10 | 4 | 2 | 6 |
| 2020 9 | 11 | 13 | 24 |
| 2020 8 | 9 | 14 | 23 |
| 2020 7 | 11 | 13 | 24 |
| 2020 6 | 14 | 10 | 24 |
| 2020 5 | 10 | 14 | 24 |
| 2020 4 | 5 | 2 | 7 |
| 2020 3 | 2 | 6 | 8 |
| 2020 2 | 0 | 1 | 1 |
| 2020 1 | 0 | 4 | 4 |
| 2019 12 | 0 | 6 | 6 |
| 2019 11 | 0 | 3 | 3 |
| 2019 10 | 0 | 1 | 1 |
| 2019 9 | 0 | 3 | 3 |
| 2019 8 | 0 | 1 | 1 |
| 2019 7 | 0 | 5 | 5 |
| 2019 6 | 0 | 5 | 5 |
| 2019 5 | 0 | 27 | 27 |
| 2019 4 | 0 | 8 | 8 |
| 2019 2 | 0 | 4 | 4 |
| 2018 12 | 0 | 3 | 3 |
| 2018 10 | 0 | 5 | 5 |
| 2018 5 | 1 | 2 | 3 |
| 2018 4 | 6 | 0 | 6 |
| 2018 3 | 5 | 1 | 6 |
| 2018 2 | 10 | 3 | 13 |
| 2018 1 | 12 | 5 | 17 |
| 2017 12 | 4 | 0 | 4 |
| 2017 11 | 12 | 1 | 13 |
| 2017 10 | 10 | 3 | 13 |
| 2017 9 | 11 | 1 | 12 |
| 2017 8 | 5 | 0 | 5 |
| 2017 7 | 17 | 1 | 18 |
| 2017 6 | 12 | 14 | 26 |
| 2017 5 | 18 | 5 | 23 |
| 2017 4 | 19 | 11 | 30 |
| 2017 3 | 22 | 16 | 38 |
| 2017 2 | 24 | 9 | 33 |
| 2016 1 | 16 | 4 | 20 |
| 2016 12 | 28 | 7 | 35 |
| 2016 11 | 28 | 8 | 36 |
| 2016 10 | 24 | 11 | 35 |
| 2016 9 | 32 | 7 | 39 |
| 2016 8 | 26 | 7 | 33 |
| 2016 7 | 25 | 1 | 26 |
| 2016 6 | 28 | 13 | 41 |
| 2016 5 | 20 | 19 | 39 |
| 2016 4 | 24 | 9 | 33 |
| 2016 3 | 26 | 11 | 37 |
| 2016 2 | 21 | 11 | 32 |
| 2015 1 | 18 | 9 | 27 |
| 2015 12 | 16 | 7 | 23 |
| 2015 11 | 23 | 4 | 27 |
| 2015 10 | 23 | 7 | 30 |
| 2015 9 | 20 | 8 | 28 |
| 2015 8 | 13 | 3 | 16 |
| 2015 7 | 13 | 6 | 19 |
| 2015 6 | 18 | 5 | 23 |
| 2015 5 | 24 | 10 | 34 |
| 2015 4 | 14 | 6 | 20 |
| 2015 3 | 16 | 2 | 18 |
| 2015 2 | 30 | 3 | 33 |
| 2015 1 | 41 | 3 | 44 |
| 2014 12 | 55 | 4 | 59 |
| 2014 11 | 41 | 1 | 42 |
| 2014 10 | 47 | 2 | 49 |
| 2014 9 | 51 | 2 | 53 |
| 2014 8 | 28 | 1 | 29 |
| 2014 7 | 69 | 1 | 70 |
| 2014 6 | 59 | 0 | 59 |
| 2014 5 | 33 | 1 | 34 |
| 2014 4 | 40 | 2 | 42 |
| 2014 3 | 41 | 1 | 42 |
| 2014 2 | 32 | 0 | 32 |
| 2014 1 | 32 | 3 | 35 |
| 2013 12 | 31 | 3 | 34 |
| 2013 11 | 32 | 3 | 35 |
| 2013 10 | 56 | 4 | 60 |
| 2013 9 | 22 | 5 | 27 |
| 2013 8 | 47 | 4 | 51 |
| 2013 7 | 34 | 1 | 35 |
| 2010 9 | 646 | 0 | 646 |
Mostrar todo
